TW200621753A - Pyrimidinylimidazoles and methods of making and using the same - Google Patents
Pyrimidinylimidazoles and methods of making and using the sameInfo
- Publication number
- TW200621753A TW200621753A TW094129857A TW94129857A TW200621753A TW 200621753 A TW200621753 A TW 200621753A TW 094129857 A TW094129857 A TW 094129857A TW 94129857 A TW94129857 A TW 94129857A TW 200621753 A TW200621753 A TW 200621753A
- Authority
- TW
- Taiwan
- Prior art keywords
- pyrimidinylimidazoles
- making
- methods
- same
- alk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60604504P | 2004-08-31 | 2004-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200621753A true TW200621753A (en) | 2006-07-01 |
Family
ID=35431931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094129857A TW200621753A (en) | 2004-08-31 | 2005-08-31 | Pyrimidinylimidazoles and methods of making and using the same |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1786802A1 (fr) |
JP (1) | JP2008511631A (fr) |
AU (1) | AU2005280168A1 (fr) |
CA (1) | CA2578630A1 (fr) |
TW (1) | TW200621753A (fr) |
WO (1) | WO2006026306A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006044509A2 (fr) * | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Procede pour traiter des lesions vasculaires |
MX2009003518A (es) | 2006-10-03 | 2009-08-25 | Genzyme Corp | Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar. |
CN101743234A (zh) | 2007-04-30 | 2010-06-16 | 雅培制药有限公司 | 二酰甘油o-酰基转移酶1型酶的抑制剂 |
CN101910153B (zh) * | 2008-01-11 | 2014-01-22 | 诺华股份有限公司 | 作为激酶抑制剂的嘧啶类 |
US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
EP2660314A4 (fr) | 2010-12-27 | 2014-09-03 | Lsip Llc | CELLULES SPi ET LEUR PROCÉDÉ DE PRODUCTION |
WO2012167261A2 (fr) * | 2011-06-03 | 2012-12-06 | Yale University | Compositions et méthodes de traitement et de prévention d'une sténose néointimale |
WO2013014262A1 (fr) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de diagnostic et de traitement du syndrome de myhre |
MX2014004994A (es) | 2011-10-26 | 2014-08-27 | Seattle Children S Res Inst | Cisteamina en el tratamiento de enfermedad fibrotica. |
KR102334260B1 (ko) | 2013-03-14 | 2021-12-02 | 스미토모 다이니폰 파마 온콜로지, 인크. | Jak2 및 alk2 억제제 및 이들의 사용 방법 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
WO2015135138A1 (fr) * | 2014-03-11 | 2015-09-17 | Yi-Wen Wang | Composition pharmaceutique et méthode pour réduire la formation de cicatrices |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
US11541149B2 (en) | 2015-12-11 | 2023-01-03 | Research Institute At Nationwide Children's Hospital | Systems and methods for optimized patient specific tissue engineering vascular grafts |
KR20210038906A (ko) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 |
EP3947737A2 (fr) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
CA2498047C (fr) * | 2002-09-18 | 2009-05-19 | Pfizer Products Inc. | Composes d'imidazole utilises en tant qu'inhibiteurs du facteur de croissance transformant (tgf) |
-
2005
- 2005-08-24 AU AU2005280168A patent/AU2005280168A1/en not_active Abandoned
- 2005-08-24 JP JP2007530093A patent/JP2008511631A/ja not_active Withdrawn
- 2005-08-24 CA CA002578630A patent/CA2578630A1/fr not_active Abandoned
- 2005-08-24 EP EP05789340A patent/EP1786802A1/fr not_active Withdrawn
- 2005-08-24 WO PCT/US2005/030133 patent/WO2006026306A1/fr active Application Filing
- 2005-08-31 TW TW094129857A patent/TW200621753A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005280168A1 (en) | 2006-03-09 |
EP1786802A1 (fr) | 2007-05-23 |
WO2006026306A1 (fr) | 2006-03-09 |
JP2008511631A (ja) | 2008-04-17 |
CA2578630A1 (fr) | 2006-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200621753A (en) | Pyrimidinylimidazoles and methods of making and using the same | |
RS20050199A (en) | Imidazolopyridines and methods of making and using the same | |
TW200621752A (en) | Pyrimidinylpyrazoles and methods of making and using the same | |
UA81624C2 (ru) | Тризамещённые гетероарилы и способ их получения и применение | |
RS20050616A (en) | Pyrazoles and methods of making and using the same | |
MXPA05002443A (es) | Pirazolopiridinas y metodos para elaboracion y uso de las mismas. | |
WO2007120980A3 (fr) | Composés de 2,4-pyrimidinediamine pour le traitement ou la prévention de maladies autoimmunes | |
WO2004013120A8 (fr) | Nouveaux benzodioxoles | |
HK1083838A1 (en) | A2a adenosine receptor antagonists | |
GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
GB0325956D0 (en) | Novel compounds | |
WO2003093269A3 (fr) | Pyrazolopyrimidine-4-one substituee | |
MY153719A (en) | Prokineticin 1 receptor antagonists | |
WO2007079163A3 (fr) | Antagonistes du recepteur de la prokineticine 1 | |
TW200716566A (en) | Prokineticin 2 receptor antagonists | |
TW200510301A (en) | Novel compounds | |
TW200510303A (en) | Novel compounds | |
WO2004014322A3 (fr) | Compositions immunomodulatrices, leurs methodes de preparation et utilisation | |
GB0510143D0 (en) | Novel compounds A1 | |
WO2005075450A3 (fr) | Nouveaux composes spiro-pentacycliques | |
HK1068136A1 (en) | Muscarinic antagonists | |
MY142804A (en) | Nk1 antagonists | |
DK1551803T3 (da) | Azabicycloderivater som muskarine receptorantagonister | |
PL371127A1 (en) | 6-aminomorphinane derivatives, method for the production and use thereof | |
GB0322510D0 (en) | Novel compounds |